Key points from article :
Infinity Bio, a Baltimore-based biotech startup, has raised $8 million in Series A funding to expand its cutting-edge immune system intelligence platform. Founded in 2023, the company aims to revolutionize our understanding of inflammation and age-related diseases through large-scale, high-quality antibody profiling. At the heart of its work is a proprietary technology called MIPSA (Molecular Indexing of Proteins by Self Assembly), developed in the Laboratory of Precision Immunology at Johns Hopkins University.
Led by Dr. Ben Larman, associate professor of pathology at Johns Hopkins, Infinity Bio is building tools to analyse the “antibody reactome” — the complete set of antibodies circulating in the body. MIPSA merges genomics, proteomics, and bioinformatics to allow researchers to screen thousands of antibody-antigen interactions simultaneously. This enables deeper insight into immune system behaviour, chronic inflammation, and diseases associated with ageing, including opportunities for better biomarker discovery, monoclonal antibody development, and vaccine design.
With the new funding — backed by Illumina Ventures, PTX Capital, Blackbird BioVentures, and Propel Baltimore Fund — Infinity Bio plans to scale its operations and expand partnerships with researchers, biotech companies, and public health bodies. The company also acquired immune profiling firm Serimmune, strengthening its tech portfolio and setting the stage for new services in late 2025.
As interest in the “reactome” grows, Infinity Bio’s approach could become a cornerstone in longevity research and precision immunology. Its platform has the potential to clarify how immune responses to infections, the microbiome, and environmental irritants influence healthspan and disease progression — unlocking new tools for diagnosis and treatment.
